Tertensam

Quick links to important sections

Tertensam

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tertensam

Property Description
Active Ingredients Amlodipine, Indapamide
Form Oral tablets (Fixed-Dose Combination)
Pharmacological Class Antihypertensive Agents
Common Use Management of high blood pressure (Hypertension)
Origin Synthetic

Tertensam is a synthetic, fixed-dose combination (FDC) product, provided as an oral tablet, fundamentally classified as an antihypertensive agent used to manage high blood pressure. This medicine is clinically recognized for consolidating two distinct classes of blood pressure-lowering compounds into a single form, offering a multi-mechanism approach that simplifies complex treatment regimens.

What Type of Antihypertensive Agent is Tertensam?

Tertensam is a prescription-only, dual combination therapy designed for oral intake. This product is a fixed-dose combination (FDC), meaning two established active ingredients are perpetually combined in a single tablet, which is a key distinguishing feature from protocols requiring the concurrent use of two separate pills. The use of this single-pill combination aligns with medical strategies supporting enhanced blood pressure control in adult patients who have not achieved their target levels with monotherapy.

The Dual Active Ingredients: Amlodipine and Indapamide

The medication's efficacy stems from its two distinct active ingredients: Amlodipine and Indapamide. Amlodipine is a dihydropyridine calcium channel blocker (CCB), a class of drugs that acts to promote vasodilation (vessel relaxation). Indapamide is categorized as a thiazide-like diuretic, which assists the body in eliminating excess salt and water through the kidneys. This dual structure achieves an enhanced synergistic increase in efficacy over either compound used alone.

Tertensam's Primary Role in Managing Hypertension

The general purpose of Tertensam is to achieve sustained and effective blood pressure reduction through its combined physiological actions: easing tension on the arteries and decreasing fluid volume. This multi-mechanism approach is intended to manage the chronic condition of hypertension by lowering the total resistance and volume in the circulatory system. This reliable lowering of blood pressure is crucial for mitigating the long-term risk of associated severe cardiovascular events, such as stroke and myocardial infarction, in adult patients.

What side effects are possible with Tertensam?

Possible Side Effects and Safety Information

The safety profile for this fixed-dose combination reflects the known adverse reactions of its two components, Amlodipine and Indapamide, classified by frequency and System-Organ Class (SOC) in official regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently documented effects, classified as Common (affecting 1 to 10 users in 100), typically involve the Nervous System and General Disorders. These may include headache, dizziness, fatigue, and peripheral oedema (ankle swelling), which is officially linked to the Amlodipine component. Other effects, such as insomnia and rash, are typically classified as Uncommon.

Serious Adverse Reactions and Safety Constraints

Very Rare but serious reactions documented in regulatory sources include angioedema (a severe swelling reaction), pancreatitis, hepatitis, and conditions such as myocardial infarction (heart attack). The Indapamide component is also associated with a major risk of electrolyte imbalance, particularly hypokalaemia (low potassium) and hyponatraemia (low sodium), which necessitates regular monitoring throughout long-term use.

This medicine is officially contraindicated in several conditions as listed in the prescribing information, including:

  • Severe renal failure (Creatinine clearance below 30 mL/min).
  • Severe hepatic impairment or hepatic encephalopathy.
  • Pre-existing hypokalaemia.
  • Severe hypotension, cardiogenic shock, or high grade aortic stenosis.

Safety documentation also specifies time-related patterns, noting that common effects like headache or somnolence are often reported as being more evident at the beginning of the treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Tertensam based on the specific toxicities of its two components. An overdose may present with signs of profound hypotension and marked peripheral vasodilation due to the Amlodipine component. The Indapamide component contributes to severe electrolyte disturbances, specifically hypokalaemia and hyponatraemia, leading to symptoms such as weakness and confusion.

The most serious documented outcomes requiring urgent medical attention include the risk of progression to shock (including cardiogenic shock) and severe arrhythmias, such as Torsades de Pointes, secondary to severe electrolyte imbalance.

Regulatory instructions mandate that if a massive overdose is suspected, active cardiac and respiratory monitoring must be initiated. Management is primarily symptomatic and supportive, including elevation of the extremities and judicious administration of fluids; the official profile notes that hemodialysis is not likely to be of benefit.

Specific considerations for overdose include an increased risk of hepatic encephalopathy for individuals with pre-existing hepatic impairment due to the Indapamide component. Frequent blood pressure measurements and monitoring of plasma electrolytes are essential components of the required observation protocol.

Therapeutic Uses of Tertensam

Tertensam is commonly used for the long-term management of essential hypertension (high blood pressure) in adult patients whose condition is not adequately controlled by monotherapy. This combination is applied across conditions marked by increased physiological stress and helps address the cluster of symptoms related to systemic imbalance, specifically elevated pressure and fluid volume excess. The primary therapeutic indications include essential hypertension and use in patients requiring the combined therapeutic effects of two distinct antihypertensive classes.

The key therapeutic benefit involves support in achieving and maintaining blood pressure reduction. This level of control is commonly associated with supporting the reduction of long-term cardiovascular risks, which may include associated serious outcomes. The single-pill format also provides the benefit of reduced pill burden, which supports patient adherence and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Support for Chronic Vascular Stress
Tertensam contributes to easing the physiological burden associated with elevated pressure, supporting general well-being during symptomatic phases.

Regulatory References

  1. Public Assessment Report from the Dutch Medicines Evaluation Board (MEB)

Eligibility and Restrictions for Use

Population Eligibility for Tertensam

The official regulatory documentation establishes strict rules for who can and cannot use Tertensam, primarily confining use to adult patients for the management of high blood pressure.


Absolute Contraindications

Use is contraindicated and explicitly prohibited for specific populations and conditions:

  • Organ Function: Patients with severe renal failure (creatinine clearance below 30 mL/min) or severe impairment of liver function (including hepatic encephalopathy).
  • Systemic Status: Individuals with hypokalaemia (abnormally low potassium), severe hypotension, or shock.
  • Cardiovascular Status: Severe conditions such as obstruction of the left ventricular outflow tract or haemodynamically unstable heart failure after acute myocardial infarction.
  • Hypersensitivity: Known sensitivity to Amlodipine, Indapamide, or related sulfonamide/dihydropyridine drug classes.

Age and Life Stage Restrictions

Use is contraindicated for women who are lactating (breastfeeding), and is generally not recommended during pregnancy. For children and adolescents (under 18 years), use is not recommended because safety and efficacy have not been established. Special caution is required for use in older adults and patients with mild to moderate hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Tertensam (Amlodipine/Indapamide) is defined by pharmacokinetic and pharmacodynamic constraints officially documented in regulatory labels. The Amlodipine component is subject to pharmacokinetic interference, particularly from substances that modulate the CYP3A enzyme pathway. Co-administration with strong or moderate CYP3A inhibitors results in a significant increase in the systemic exposure of Amlodipine.

The Indapamide component contributes to pharmacodynamic and electrolyte synergy and carries specific restrictions. Combining Indapamide with medicines that prolong the QT interval is associated with an elevated risk of severe ventricular arrhythmias, specifically Torsades de Pointes, due to the potential for hypokalemia. Systemic Non-steroidal Anti-inflammatory Drugs (NSAIDs) may cause a reduction in the antihypertensive effect.

Regulatory documentation establishes key co-administration constraints:

  • Simvastatin Dose Restriction: The dose of Simvastatin must not exceed 20 mg per day when co-administered with Amlodipine, due to a documented increase in Simvastatin's systemic exposure.
  • Lithium Co-administration: Combination is not recommended due to the risk of increased Lithium plasma concentrations and toxicity.

Interactions with consumables include Grapefruit or Grapefruit Juice, which may increase Amlodipine systemic exposure, and the herbal product St. John's Wort, classified as a CYP3A inducer that can decrease Amlodipine plasma levels. The combination is contraindicated in patients with severe renal impairment or uncorrected hypokalemia.

Mechanism of Action

Tertensam decreases pressure within the circulatory system through the synchronized action of two independent pharmacological agents, each modulating a core physiological factor: peripheral resistance and fluid volume.

Modulation of Arterial Smooth Muscle Tone

The Amlodipine component operates by targeting the vascular tone pathway. It functions as an inhibitor by blocking the L-type calcium channels in the walls of the peripheral arteries. This molecular interference prevents the influx of calcium ions, which are essential for muscle contraction, resulting in arterial vasodilation (widening). The consequence of this mechanism is a reduction in Total Peripheral Resistance (TPR), which lowers the physical load (afterload) exerted on the circulatory system.

Regulation of Renal Fluid and Electrolyte Balance

The Indapamide component primarily engages the renal fluid and salt homeostasis pathway. It acts as an inhibitor of the Sodium-Chloride cotransporter (NCC) in the kidney tubules. By suppressing the reabsorption of sodium and chloride ions, this mechanism facilitates increased water excretion (natriuresis). The resulting physiological effect is a decrease in the extracellular fluid volume and circulating plasma volume, which modulates pressure within the systemic circulation.

Dosage and Administration Information

How to Use Tertensam

The usage of this fixed-dose combination (FDC) product, containing amlodipine and indapamide, follows procedural instructions. The medicine is intended for the long-term management of essential hypertension and is used only as a substitution therapy in adult patients. This means it is restricted to those whose blood pressure is already adequately controlled by taking the individual components concurrently at the same dose levels.

Administration Protocol

The product is administered orally as a single, fixed tablet strength, once daily, preferably taken in the morning. The tablets are specifically formulated as modified-release and must be swallowed whole with water. It is a procedural requirement that the tablet must not be crushed, chewed, or broken to ensure the intended release characteristics are maintained. Any required adjustment to the overall therapeutic dosage must be executed by switching back to the individual single-component medications; the FDC tablet is not suitable for dose titration.

Dosage Strengths and Special Use Populations

Official strengths combine 1.5 mg of Indapamide with either 5 mg or 10 mg of Amlodipine. The maximum daily dose is fixed at one tablet of the highest available strength (1.5 mg/10 mg). Specific usage constraints apply to certain populations. For patients with mild to moderate hepatic impairment, cautious dose selection may be necessary, and use in those with severe hepatic or renal impairment is restricted. Safety and efficacy data are not established for use in children and adolescents.

Recent Clinical Evidence

Research evidence / Overview of studies for Tertensam

Studies in Conditions Characterized by Fluctuating or Episodic Manifestations

Tertensam was studied for its application in people managing conditions characterized by fluctuating or episodic manifestations (high blood pressure). This research examined various patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. The studies were often applied in studies examining patient-reported experiences in observational settings monitoring daily-life functioning.

The research explored patterns observed in the studies, examining how symptoms change over time. When studies were conducted during periods of increased symptom activity, the data show patterns related to changes that were measured during the study period, particularly related to outcomes related to physical discomfort. The studies contribute to understanding short-term changes observed in these populations.

However, the evidence is limited when considering the long-term application of Tertensam for this condition. Follow-up durations were limited across many of the central studies, and as a result, long-term effects are not fully established. Also, sample sizes were modest in some trials, meaning results apply only to the populations studied. Research contributes to the broader evidence landscape but does not determine whether an individual will respond similarly.


Research in Conditions Associated with Acute or Disruptive Episodes

Tertensam was also studied for use in research contexts involving conditions associated with acute or disruptive episodes. These studies explored outcomes describing episodic or acute changes and outcomes capturing phases of heightened symptom activity. The research examined symptom patterns when patients experienced temporary physiological imbalance.

The findings help contextualize the variability in outcomes linked to inflammatory or irritative states. For this research scenario, comparative evidence is lacking, and evidence quality varies across studies. This means that the certainty remains low when comparing these findings against other research. The study results reflect the specific conditions under which they were conducted, and evidence highlights what is known and what is still uncertain.

Key Studies & References

  1. Public Assessment Report for Tertiary (Amlodipine/Indapamide) - Regulatory Document

Frequently Asked Questions (FAQ)

Common questions about Tertensam (FAQ)

Q: How quickly does Tertensam start lowering blood pressure?

A: Regulatory information indicates that the blood pressure-lowering effect for the Amlodipine component starts gradually over several hours after administration. However, because Tertensam is taken once daily, the full, steady-state effect of the medication typically develops over several days of continued use.

Q: Does Tertensam cause tiredness or fatigue?

A: Yes, regulatory documents list fatigue and asthenia (a medical term for unusual weakness or lack of energy) as common side effects. These effects are often more noticeable when treatment is first started.

Q: Does Tertensam interact with common pain relievers like ibuprofen?

A: Official information warns that Systemic Non-steroidal Anti-inflammatory Drugs (NSAIDs) may interfere with the blood pressure-lowering action of Tertensam. Since common pain relievers like ibuprofen are NSAIDs, patients are typically advised to discuss their use with a healthcare professional due to the potential for reduced efficacy.

Q: Can I take Tertensam if I also take supplements like magnesium or calcium?

A: While specific mineral supplements are not explicitly listed in the official warnings, the Indapamide component can affect the body's electrolyte balance, particularly potassium levels. Due to the potential for electrolyte interference, patients are advised to confirm the safety of any mineral supplements with a healthcare provider.

Q: Are there any foods or drinks I should avoid while on Tertensam?

A: Yes, regulatory documents advise against consuming Grapefruit or Grapefruit Juice. Grapefruit can potentially increase the amount of the Amlodipine component that is absorbed into the bloodstream, which may heighten the risk of side effects, and is typically discouraged by official prescribing information.

Q: Can people with diabetes safely take Tertensam?

A: Regulatory warnings state that patients with diabetes should use Tertensam with caution. Official warnings state that the Indapamide component may cause disturbances in glucose metabolism. Due to this risk, official documentation highlights that monitoring of blood sugar levels may be necessary for patients with diabetes mellitus.

Q: Can Tertensam affect kidney function?

A: Official safety information indicates that the medication is strictly prohibited in patients with severe renal failure. For patients with milder or normal kidney function, caution is required, and official information indicates that monitoring of kidney function during long-term use is typically part of the treatment protocol.

Q: Can Tertensam be taken with alcohol?

A: Although alcohol is not an absolute contraindication, it should be consumed with caution. Alcohol can increase the blood pressure-lowering effects of the medication and may worsen certain side effects like dizziness or lightheadedness.

Q: Will stopping Tertensam suddenly cause any problems?

A: The Amlodipine component in Tertensam has a very long half-life, meaning blood pressure returns to normal gradually if the medication is stopped. Official guidance indicates that any changes or discontinuation of therapy should be performed under medical supervision.

Q: Does Tertensam affect blood sugar levels?

A: Official warnings state that the Indapamide component, which is a diuretic, can potentially cause metabolic changes. This may include changes in blood glucose levels. Due to this potential, monitoring of blood sugar levels may be necessary, particularly for those with existing glucose control issues.

Q: What happens if I miss a dose of Tertensam?

A: If a dose is missed, official regulatory guidance advises the patient to skip that missed dose completely. The next scheduled dose should then be taken at the usual time the following day. The guidance also strongly advises against taking a double dose to make up for a missed one.

Q: How long does Tertensam stay in your system?

A: The Amlodipine component has a prolonged elimination half-life, meaning it takes a long time for the drug's concentration to fall in the body. The half-life ranges from 40 to 60 hours, so the effects persist for several days after administration.

Q: What is the purpose of the combination of ingredients in Tertensam?

A: Tertensam is a fixed-dose combination product that is intended to simplify blood pressure treatment. It brings together two distinct mechanisms of action—artery relaxation and fluid/salt reduction—into a single pill, which is effective for patients whose blood pressure is already well-controlled on the individual components.

Q: Does Tertensam need to be taken at a specific time of day?

A: Official administration instructions specify that the product should be taken once daily. It is recommended that the tablet be taken preferably in the morning.

Q: Is a dry cough associated with taking Tertensam?

A: Cough is listed in the official safety profile as an Uncommon side effect, meaning it is not frequently reported. While dry cough is more commonly associated with a different class of blood pressure medicine, it can still occur with the Amlodipine component.

Q: What should I do if my blood pressure still seems high after starting Tertensam?

A: The fixed-dose tablet is not designed to allow for dose changes or titration. If the blood pressure is not adequately controlled, regulatory information states that any required dosage adjustment must be done by switching back to the individual single-component medicines under a healthcare professional’s guidance.

Q: Is it safe to drive or operate machinery while taking Tertensam?

A: Official documents caution that the medicine may have a minor to moderate influence on the ability to drive or operate machinery. This warning is based on the risk of common side effects like dizziness, fatigue, or headache, especially during the initial phase of treatment.

Q: Are there any known allergic reactions to Tertensam?

A: Yes, official warnings classify a known hypersensitivity to the drug components as a contraindication. Furthermore, a serious allergic reaction called angioedema (severe swelling) is documented as a very rare potential adverse effect.

Q: What is the difference between Tertensam and a beta-blocker?

A: Tertensam contains two active ingredients that belong to the calcium channel blocker and thiazide-like diuretic classes of medicine. Beta-blockers belong to a third, entirely different pharmacological class that works through a different mechanism to lower blood pressure.

Q: Can Tertensam cause muscle cramps?

A: Yes, regulatory safety documents list muscle cramps as a common side effect. This is likely related to the Indapamide component’s action on fluid and electrolyte balance.

Q: Can Tertensam be taken with common cold and flu medicines?

A: Common cold and flu medicines often contain ingredients like NSAIDs (pain relievers) or decongestants that can interfere with blood pressure medications. Official interaction warnings related to NSAIDs apply here. Therefore, patients are typically advised to confirm the specific product ingredients with a healthcare professional to check for potential interactions.

Q: Is Tertensam a first-line treatment for high blood pressure?

A: No, Tertensam is not indicated as a first-line therapy. Official regulatory documents specify that it is intended only for substitution therapy in adult patients. This means it is for patients whose high blood pressure is already well-controlled by taking the individual components separately.

Q: Can the heat affect how Tertensam works?

A: The diuretic component of Tertensam increases the body's excretion of water and salt, which can raise the risk of dehydration and electrolyte imbalance. This risk is naturally increased by hot weather or heavy physical activity.

Q: Can Tertensam make you feel jittery or anxious?

A: Official safety data lists mood changes, including anxiety, as an uncommon side effect of the medication. Insomnia (difficulty sleeping) is also listed as an uncommon side effect.

Q: What distinguishes Tertensam from straight perindopril?

A: Tertensam is a fixed-dose combination of a calcium channel blocker and a thiazide-like diuretic. Perindopril is a single-ingredient drug that belongs to a different class of medicine called an ACE inhibitor, which has a different primary mechanism of action.

Q: Does Tertensam help with fluid retention or swelling?

A: The Indapamide component is a diuretic, meaning it is designed to increase the excretion of water and salt through the kidneys. This action helps to reduce excess fluid volume in the body.

Q: Is weight gain a common side effect of Tertensam?

A: Weight gain is not listed as a common side effect. However, a slight weight increased is listed as an uncommon adverse reaction in the official safety profile.

Q: Can Tertensam cause dizziness or lightheadedness?

A: Yes, dizziness is listed as a Common side effect. Lightheadedness, especially when standing up, may be related to the blood pressure-lowering effect. Syncope (fainting) is listed as an Uncommon side effect.

Q: What is the difference between Tertensam and other 'water pills'?

A: Tertensam is a fixed-dose combination containing Indapamide, which is a thiazide-like diuretic (a type of 'water pill'). However, it is fundamentally a combination medicine because it also contains Amlodipine, a calcium channel blocker, to provide a dual action on blood pressure.

How should Tertensam be stored and disposed of?

Official Storage and Disposal Requirements

Tertensam (Amlodipine/Indapamide) must be stored and handled according to the specific conditions defined by regulatory labeling to maintain the tablets' stability.


Storage Conditions

Requirement Details
Temperature Store below 30°C (86°F).
Protection Store in the original package to protect from light.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Any unused or expired Tertensam, along with associated waste material, must be disposed of in accordance with local requirements. The medicine should not be discarded via wastewater or household trash to avoid environmental contamination. These procedures ensure the appropriate handling of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tertensam found in:

A-Z Index: